2006年澳大利亚免疫接种后不良事件监测年度报告。

Glenda L Lawrence, Padmasiri E Aratchige, Ian Boyd, Peter B McIntyre, Michael S Gold
{"title":"2006年澳大利亚免疫接种后不良事件监测年度报告。","authors":"Glenda L Lawrence, Padmasiri E Aratchige, Ian Boyd, Peter B McIntyre, Michael S Gold","doi":"10.33321/cdi.2007.31.27","DOIUrl":null,"url":null,"abstract":"<p><p>This report summarises Australian passive surveillance data for adverse events following immunisation (AEFI) reported to the Adverse Drug Reactions Advisory Committee for 2006, and describes reporting trends over the seven-year period 2000 to 2006. There were 779 AEFI records for vaccines administered in 2006. This is an annual AEFI reporting rate of 3.8 per 100,000 population, the lowest since 2002 and a 10% decrease compared with 2005 (869 AEFI records; 4.3 records per 100,000 population). Dose-based AEFI reporting rates in 2006 were 1.9 per 100,000 doses of influenza vaccine for adults aged > or = 18 years, 19.1 per 100,000 doses of pneumococcal polysaccharide vaccine for those aged > or = 65 years and 12.5 per 100,000 doses of scheduled vaccines for children aged < 7 years. Trend data showed transient increases in reporting of AEFI following the introduction of DTPa-IPV combination vaccines in November 2005 for children aged < 7 years. The majority of the 779 AEFI records for 2006 described non-serious events while 11% (n = 85) described AEFIs defined as serious. There was one report of death temporally associated with receipt of dTpa-IPV and typhoid vaccines in an adult with a history of a chronic medical condition. The most frequently reported individual AEFI was injection site reaction in children following a fourth or fifth dose of acellular pertussis-containing vaccine (70 reports per 100,000 doses). The data confirm the low rate of AEFI reported in Australia and demonstrate the ability of the system to detect and investigate signals such as those associated with changes in immunisation programs.</p>","PeriodicalId":350023,"journal":{"name":"Communicable diseases intelligence quarterly report","volume":" ","pages":"269-82"},"PeriodicalIF":0.0000,"publicationDate":"2007-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Annual report on surveillance of adverse events following immunisation in Australia, 2006.\",\"authors\":\"Glenda L Lawrence, Padmasiri E Aratchige, Ian Boyd, Peter B McIntyre, Michael S Gold\",\"doi\":\"10.33321/cdi.2007.31.27\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This report summarises Australian passive surveillance data for adverse events following immunisation (AEFI) reported to the Adverse Drug Reactions Advisory Committee for 2006, and describes reporting trends over the seven-year period 2000 to 2006. There were 779 AEFI records for vaccines administered in 2006. This is an annual AEFI reporting rate of 3.8 per 100,000 population, the lowest since 2002 and a 10% decrease compared with 2005 (869 AEFI records; 4.3 records per 100,000 population). Dose-based AEFI reporting rates in 2006 were 1.9 per 100,000 doses of influenza vaccine for adults aged > or = 18 years, 19.1 per 100,000 doses of pneumococcal polysaccharide vaccine for those aged > or = 65 years and 12.5 per 100,000 doses of scheduled vaccines for children aged < 7 years. Trend data showed transient increases in reporting of AEFI following the introduction of DTPa-IPV combination vaccines in November 2005 for children aged < 7 years. The majority of the 779 AEFI records for 2006 described non-serious events while 11% (n = 85) described AEFIs defined as serious. There was one report of death temporally associated with receipt of dTpa-IPV and typhoid vaccines in an adult with a history of a chronic medical condition. The most frequently reported individual AEFI was injection site reaction in children following a fourth or fifth dose of acellular pertussis-containing vaccine (70 reports per 100,000 doses). The data confirm the low rate of AEFI reported in Australia and demonstrate the ability of the system to detect and investigate signals such as those associated with changes in immunisation programs.</p>\",\"PeriodicalId\":350023,\"journal\":{\"name\":\"Communicable diseases intelligence quarterly report\",\"volume\":\" \",\"pages\":\"269-82\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Communicable diseases intelligence quarterly report\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33321/cdi.2007.31.27\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Communicable diseases intelligence quarterly report","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33321/cdi.2007.31.27","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本报告总结了2006年澳大利亚向药物不良反应咨询委员会报告的免疫后不良事件(AEFI)被动监测数据,并描述了2000年至2006年七年间的报告趋势。2006年接种的疫苗有779份AEFI记录。这是AEFI报告的年度比率,每10万人中有3.8人,这是自2002年以来的最低水平,与2005年(869个AEFI记录;每10万人4.3条记录)。2006年以剂量为基础的AEFI报告率为:>或= 18岁成人流感疫苗每10万剂1.9例,>或= 65岁肺炎球菌多糖疫苗每10万剂19.1例,7岁以下儿童计划接种疫苗每10万剂12.5例。趋势数据显示,2005年11月为7岁以下儿童引入百白破- ipv联合疫苗后,急性脑损伤报告出现短暂增加。2006年的779份AEFI记录中,大多数描述了非严重事件,而11% (n = 85)描述了被定义为严重的AEFI。有一份报告称,一名有慢性病史的成年人因接种白喉白破- ipv和伤寒疫苗而暂时死亡。最常报告的个体AEFI是儿童在接种第四剂或第五剂含百日咳的无细胞百日咳疫苗后的注射部位反应(每10万剂中有70例报告)。这些数据证实了澳大利亚报告的AEFI发生率较低,并证明了该系统能够检测和调查诸如与免疫规划变化相关的信号。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Annual report on surveillance of adverse events following immunisation in Australia, 2006.

This report summarises Australian passive surveillance data for adverse events following immunisation (AEFI) reported to the Adverse Drug Reactions Advisory Committee for 2006, and describes reporting trends over the seven-year period 2000 to 2006. There were 779 AEFI records for vaccines administered in 2006. This is an annual AEFI reporting rate of 3.8 per 100,000 population, the lowest since 2002 and a 10% decrease compared with 2005 (869 AEFI records; 4.3 records per 100,000 population). Dose-based AEFI reporting rates in 2006 were 1.9 per 100,000 doses of influenza vaccine for adults aged > or = 18 years, 19.1 per 100,000 doses of pneumococcal polysaccharide vaccine for those aged > or = 65 years and 12.5 per 100,000 doses of scheduled vaccines for children aged < 7 years. Trend data showed transient increases in reporting of AEFI following the introduction of DTPa-IPV combination vaccines in November 2005 for children aged < 7 years. The majority of the 779 AEFI records for 2006 described non-serious events while 11% (n = 85) described AEFIs defined as serious. There was one report of death temporally associated with receipt of dTpa-IPV and typhoid vaccines in an adult with a history of a chronic medical condition. The most frequently reported individual AEFI was injection site reaction in children following a fourth or fifth dose of acellular pertussis-containing vaccine (70 reports per 100,000 doses). The data confirm the low rate of AEFI reported in Australia and demonstrate the ability of the system to detect and investigate signals such as those associated with changes in immunisation programs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信